AMAG receives US FDA complete response for lead candidate
This article was originally published in Scrip
AMAG Pharmaceuticals has received a complete response letter from the US FDAfor its NDA on ferumoxytol, an intravenous iron replacement agent, for the treatment of iron deficiency anaemia in chronic kidney disease patients, which it submitted in December 2007.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.